GlassScriptPhysician profile
Adam Robert Duke
NPI 1710140165
$7,327.97
in general payments reported to CMS, 2019-2025
28 companies · $594 in 2025
The $594 reported for 2025 was more than what 78% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.53 · 2020: $1,069 · 2021: $2,884 · 2022: $1,542 · 2023: $673 · 2024: $477 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,744.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $2,149.17 | 2021-2024 | Axonics, Bulkamid |
| Coloplast Corp | $1,396.14 | 2019-2025 | Saffron |
| Coopersurgical, INC. | $703.46 | 2019-2025 | Paragard T 380a |
| Stryker Corporation | $695.93 | 2021 | |
| Olympus Winter & Ibe Gmbh | $660.00 | 2021 | |
| Olympus America INC. | $350.00 | 2020 | |
| Astellas Pharma US INC | $149.02 | 2023-2024 | Veozah |
| Abbvie INC. | $137.44 | 2022-2025 | Botox |
| Glaxosmithkline, LLC. | $124.16 | 2024-2025 | Nucala |
| Sumitomo Pharma America, INC. | $114.64 | 2023-2025 | Gemtesa, Myfembree |
| Merck Sharp & Dohme LLC | $114.58 | 2019-2025 | Winrevair |
| Boston Scientific Corporation | $112.59 | 2025 | Axonics |
| Hologic Sales and Service, LLC | $81.77 | 2022-2025 | Fluent Fluid Management System, Omni Hysteroscope, Myosure Tissue Removal Device |
| Pfizer INC. | $66.34 | 2023-2024 | |
| Allergan, INC. | $56.79 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $55.73 | 2024-2025 | Korlym |
| Novo Nordisk INC | $53.02 | 2022-2025 | Wegovy |
| Exact Sciences Corporation | $49.05 | 2024 | Cologuard Collection Kit |
| Organon LLC | $45.27 | 2024-2025 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $35.52 | 2024 | Tezspire |
| Lilly USA, LLC | $29.81 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $29.68 | 2025 | |
| Amgen INC. | $23.99 | 2024 | Repatha, Otezla |
| Ethicon US, LLC | $20.26 | 2025 | Vistaseal |
| Dexcom, INC. | $19.44 | 2025 | Dexcom G6 Transmitter |
| Urovant Sciences INC | $18.77 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $18.38 | 2025 | Opsynvi |
| Ascend Therapeutics US, LLC | $17.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Duke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.